Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Robin, M; Porcher, R; Zinke-Cerwenka, W; van Biezen, A; Volin, L; Mufti, G; Craddock, C; Finke, J; Richard, C; Passweg, J; Peniket, A; Maertens, J; Sucak, G; Gedde-Dahl, T; Vitek, A; Nagler, A; Blaise, D; Beelen, D; Maillard, N; Schwerdtfeger, R; de Witte, T; Kroger, N.
Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.
Bone Marrow Transplant. 2017; 52(2):209-215
Doi: 10.1038/bmt.2016.266
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Zinke-Cerwenka Wilma
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We report a retrospective analysis of 246 myelodysplastic syndrome (MDS) patients in the EBMT (The European Society for Blood and Marrow Transplantation) database who were transplanted for International Prognostic Scoring System (IPSS) low or intermediate-1 disease. The majority of these patients (76%) were reclassified as intermediate or higher risk according to R-IPSS. The 3-year overall survival (OS) and PFS were 58% and 54%, respectively. In a multivariate analysis, adverse risk factors for PFS were marrow blast percentage (hazard ratio (HR): 1.77, P=0.037), donor/recipient CMV serostatus (donor-/recipient+: HR: 2.02, P=0.011) and source of stem cells (marrow and non-CR: HR: 5.72, P<0.0001, marrow and CR: HR: 3.17, P=0.027). Independent risk factors for OS were disease status at time of transplant and the use of in vivo T-cell depletion (TCD). Patients who did not receive TCD and were transplanted from an unrelated donor had worse OS (HR: 4.08, P<0.0001). In conclusion, 'lower' risk MDS patients have better outcome than those with 'higher risk' after haematopoietic stem cell transplant (HSCT). Selecting the right source of stem cells, a CMV-positive donor for CMV-positive patients and using in vivo TCD results in the best outcome in these patients. More studies are needed to evaluate the role of HSCT in these patients as compared with conventional treatment.
- Find related publications in this database (using NLM MeSH Indexing)
- Allografts -
- Anemia, Refractory, with Excess of Blasts - mortality
- Anemia, Refractory, with Excess of Blasts - therapy
- Disease-Free Survival -
- Female -
- Follow-Up Studies -
- Hematopoietic Stem Cell Transplantation -
- Humans -
- Male -
- Registries -
- Risk Factors -
- Survival Rate -